A new drug called CAP1-hFc that blocks PCSK9 from sticking to CAP1 works better at reducing inflammation in immune cells than current PCSK9 drugs like evolocumab, which only lower cholesterol.

37

Pro

0

Against

Evidence from Studies

Supporting (1)

37

Community contributions welcome

37

PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor

Cohort Study

Human

2024 Mar 30

This study found that a special protein (CAP1-Fc) that stops PCSK9 from talking to CAP1 works better at reducing inflammation in human immune cells than a common drug (evolocumab) that only blocks PCSK9 from lowering cholesterol. So yes, the new approach is more anti-inflammatory.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor

Score: 37

DOI: 10.1038/s41467-024-46336-2

Similar Assertions

PCSK9, a protein in the blood, sticks to another protein called CAP1 on immune cells, which turns on a chain reaction that makes the cells more inflamed and sticky, even if cholesterol levels are normal — this can worsen artery plaque.

37

0

78%

PCSK9 doesn’t just cause inflammation — it also tricks immune cells into making more PCSK9, creating a cycle that keeps the inflammation going in artery plaques.

37

0

72%

Blocking a protein called PCSK9 with certain drugs helps your body remove bad cholesterol from your blood more effectively.

63

0

72%

Even when mice have too much PCSK9 and high cholesterol, if they have less of the CAP1 protein, their artery plaques don’t get as bad — proving CAP1 is needed for PCSK9 to cause inflammation.

37

0

71%